Afuco™ Anti-ITGA5 ADCC Therapeutic Antibody (Volociximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Integrin Integrin alpha 5 beta 1. Volociximab (also known as M200) is a chimeric monoclonal antibody jointly for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.
It is thought to reduce metastases. Early results show potential in renal cell cancers.
It is thought to reduce metastases. Early results show potential in renal cell cancers.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-077 |
| Pricing | Inquiry |
| Host | Chimeric |
| Target | ITGA5 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IP, IF, FuncS, FC, Neut, ELISA |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |